Vascepa is owned by Amarin Pharms.

Vascepa contains Icosapent Ethyl.

Vascepa has a total of 70 drug patents out of which 0 drug patents have expired.

Vascepa was authorised for market use on 26 July, 2012.

Vascepa is available in capsule;oral dosage forms.

Vascepa can be used as use of vascepa as an adjunct to statin therapy to reduce the risk of unstable angina in an adult patient with established cardiovascular disease, use of vascepa to reduce triglyceride levels in an adult patient having triglyceride levels of at least about 500 mg/dl, on anticoagulant/antiplatelet/thrombolytic therapy, and having atrial fibrillation and/or atrial flutter, use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death, coronary revascularization, and unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl), use of vascepa as an adjunct to statin therapy to reduce the risk of coronary revascularization in an adult patient with established cardiovascular disease, use of vascepa as an adjunct to statin therapy to reduce the occurrence of a cardiovascular event in an adult patient with hypercholesterolemia, use of vascepa to treat mixed hypertriglyceridemia in an adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy, method of reducing tg levels in patient suffering from severe hypertriglyceridemia, use of vascepa as an adjunct to statin therapy to reduce the risk of stroke in an adult patient with elevated triglycerides and atrial fibrillation, use of vascepa to reduce the incidence of stroke in an adult patient on statin therapy and with elevated triglyceride levels (>150 mg/dl), wherein the patient experiences atrial fibrillation and/or flutter instead of an incidence of stroke, use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event in an adult patient with elevated triglyceride levels and at least one risk factor for cardiovascular disease, use of vascepa to reduce triglyceride levels in an adult patient on statin therapy and having atrial fibrillation or atrial flutter and triglyceride levels of about 500 mg/dl to about 2,000 mg/dl, use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event (cardiovascular death, coronary revascularization and/or unstable angina) in an adult patient with elevated triglyceride levels, use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or coronary revascularization in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl), use of vascepa with high intensity statin therapy to reduce the risk of a cv event in an adult patient with elevated triglyceride levels and (1) established cv disease, or (2) diabetes mellitus and two or more additional risk factors for cv disease, use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death in an adult patient with established cardiovascular disease, use of vascepa to lower triglycerides and ldl-c in an adult patient with elevated triglyceride (tg) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy, use of vascepa to lower triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (tg) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy, use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event in a patient with prior percutaneous coronary intervention, use of vascepa to reduce triglyceride levels in an adult patient on statin therapy and having atrial fibrillation and triglyceride levels of greater than 500 mg/dl, use of vascepa to treat mixed dyslipidemia in an adult patient with elevated triglyceride (tg) levels (>=150 mg/dl) and on statin therapy, use of vascepa to reduce triglycerides in an adult patient with elevated triglyceride (tg) levels (about 200 mg/dl to less than about 500 mg/dl) and on rosuvastatin therapy, use of vascepa as an adjunct to statin therapy to reduce the risk of stroke in an adult patient with established cardiovascular disease, use of vascepa as an adjunct to statin therapy to reduce the risk myocardial infarction in an adult patient having atrial fibrillation or atrial flutter and elevated triglyceride levels, method of reducing tg levels in patient on statin therapy suffering from severe hypertriglyceridemia; method of reducing tg levels in patient suffering from severe hypertriglyceridemia; use of vascepa to treat hypertriglyceridemia in an adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy, use of vascepa to reduce triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy, use of vascepa as an adjunct to statin therapy to reduce the risk of a second and further cardiovascular event in an adult patient with established cardiovascular disease, use of vascepa as an adjunct to statin therapy to reduce the risk of a third and further cardiovascular event in an adult patient with elevated tg levels (>=150 mg/dl) and established cardiovascular disease; use of vascepa as an adjunct to statin therapy to reduce the risk of a second or further cardiovascular (cv) event in an adult patient with elevated tg levels (>= 150 mg/dl) and diabetes mellitus and 2 or more additional risk factors for cv disease, use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event (coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels, use of vascepa as an adjunct to statin therapy to reduce the risk of a major cardiovascular event in an adult patient with diabetes mellitus and two or more additional risk factors for cardiovascular disease, use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl), method of reducing tg levels in patient suffering from severe hypertriglyceridemia; use of vascepa to reduce triglycerides in an adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy; method of reducing tg levels in patient on statin therapy suffering from severe hypertriglyceridemia, use of vascepa to reduce the incidence of mi in an adult patient on statin therapy and with elevated triglyceride levels (>150 mg/dl), wherein the patient experiences atrial fibrillation and/or flutter instead of an incidence of mi, use of vascepa to treat hypertriglyceridemia in an adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy, use of vascepa as an adjunct to statin therapy to reduce the risk of myocardial infarction in an adult patient with elevated triglyceride levels and established cv disease or diabetes mellitus and two or more additional risk factors for cv disease, use of vascepa to lower triglycerides in an adult patient with elevated triglyceride (tg) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy, use of vascepa as an adjunct to statin therapy to reduce the risk of a cv event (cv death, coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels and diabetes mellitus, use of vascepa as an adjunct to statin therapy to reduce the risk of coronary revascularization and/or unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl), use of vascepa as an adjunct to statin therapy to reduce the risk of myocardial infarction, stroke, both in an adult patient with type 2 diabetes mellitus, use of vascepa as an adjunct to statin therapy to reduce the risk of onset and/or recurrence of cardiovascular events in a patient who has escaped the unstable period after cardiovascular angioplasty.

The generics of Vascepa are possible to be released after 28 June, 2033.